Nikang Therapeutics Inc. has described GTPase KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.

Artus Therapeutics Inc. and the Institute for Stem Cell Biology & Regenerative Medicine (Instem) have synthesized aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of ulcerative colitis.

Shouyao Holdings (Beijing) Co. Ltd. has patented inhibitors of fibroblast growth factor receptor (FGFR), particularly FGFR2 and/or FGFR3, described as potentially useful for the treatment of cancer.

Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a son of sevenless homolog 1 (SOS1) targeting moiety reported to be useful for the treatment of cancer, neurofibromatosis type 1, Costello syndrome, cardiofaciocutaneous syndrome and Noonan syndrome.

Kalvista Pharmaceuticals Ltd. has disclosed coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of hereditary angioedema and thrombotic disorder.

GSK plc has identified cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors and their prodrugs reported to be useful for the treatment of systemic lupus erythematosus or lupus nephritis.

Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Hepaitech (Beijing) Biopharma Technology Co. Ltd. has patented compounds reported to be useful for the treatment of anemia, fungal infections and HIV infections, among others.

Medshine Discovery Inc. has divulged GTPase KRAS (G12C mutant) Inhibitors reported to be useful for the treatment of cancer.

Shanghai Haihe Biopharma Co. Ltd. has described poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer.